Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Total Current Liabilities for 12 consecutive years, with $86.2 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 8.86% year-over-year to $86.2 million; the TTM value through Mar 2026 reached $86.2 million, down 8.86%, while the annual FY2025 figure was $120.1 million, 16.0% up from the prior year.
  • Total Current Liabilities hit $86.2 million in Q1 2026 for Syndax Pharmaceuticals, down from $120.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $120.1 million in Q4 2025 and bottomed at $20.8 million in Q3 2022.
  • Average Total Current Liabilities over 5 years is $61.6 million, with a median of $50.8 million recorded in 2024.
  • Year-over-year, Total Current Liabilities fell 27.55% in 2022 and then surged 166.03% in 2025.
  • Syndax Pharmaceuticals' Total Current Liabilities stood at $29.1 million in 2022, then soared by 99.88% to $58.1 million in 2023, then soared by 78.24% to $103.5 million in 2024, then grew by 16.0% to $120.1 million in 2025, then decreased by 28.26% to $86.2 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $86.2 million, $120.1 million, and $114.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.